United Therapeutics Corporation
UTHRHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, United Therapeutics Corporation focuses on Drug Manufacturers - Specialty & Generic services and products. United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United. The company carries a $22.74B market cap, placing it firmly in the large-cap category. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Market Cap
$22.74B
Beta
0.58
P/E (TTM)
19.82
P/E (Fwd)
16.21
EPS (TTM)
$27.03
EPS (Fwd)
$33.04
ROE
20.3%
ROA
12.6%
Cash
$2.15B
Total Debt
$0
Free CF
$566.4M
52W Change
83.4%
Annual Financials
Cash vs Debt
United Therapeutics Corporation reports $2.15B in cash and $0 in total debt. Annual free cash flow of $566.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 20.3% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 12.6% further supports the picture of efficient asset utilization. Revenue has grown from $1.94B (2022) to $3.18B (2025), reflecting a 64% increase over the period.
UTHR's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for United Therapeutics Corporation and its sector.